About 58% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...

DUBAI, 16th April 2025 (WAM) -- The Emirates Drug Establishment (EDE) has approved new indications for Guselkumab, making the UAE the second country globally to authorise the treatment for Crohn ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Guselkumab, the first IL-23 inhibitor with subcutaneous and intravenous options, was approved for moderate to severe Crohn disease, showing clinical remission and endoscopic response. Iptacopan ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the ...